atorvastatin – Medxy AI

Atorvastatin in Older Adults: Balancing Cardiovascular Prevention and Disability-Free Survival

By MedXY 10/28/2026

A landmark randomized trial demonstrates that atorvastatin reduces major cardiovascular events in adults aged 70 and older without established cardiovascular disease but does not extend disability-free survival, highlighting nuanced considerations for primary prevention.

Cardiology Hematology-Oncology news Oncology

Atorvastatin Preserves Aortic Elasticity During Anthracycline Chemotherapy: Secondary Analysis of STOP‑CA

By MedXY 11/25/2025

In a secondary analysis of the randomized STOP‑CA trial, atorvastatin 40 mg daily attenuated anthracycline‑associated increases in aortic stiffness measured by CMR pulse wave velocity, suggesting vascular protection and a potential strategy to reduce cardiotoxicity risk.

Cardiology Diabetes & Endocrinology news Specialties

The Long-Term Legacy of Atorvastatin: Insights from the 20-Year ASCOT-Legacy Follow-Up

By MedXY 08/13/2025

The ASCOT-Legacy study shows atorvastatin significantly reduces long-term cardiovascular events and deaths over 20 years in hypertensive patients, supporting early statin initiation for cardiovascular prevention.